

Merus Labs International Inc.  
Form 6-K  
May 15, 2013

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2013

Commission File No. 00-30082

**MERUS LABS INTERNATIONAL INC.**

(Translation of registrant's name into English)

**Suite 2007, 1177 West Hastings Street**

**Vancouver, BC V6E 2K3**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F  
**Form 20-F**  **Form 40-F**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(1)

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(7)

---

The disclosure in the Management's Discussion and Analysis for the interim period ended March 31, 2013 filed herewith updates the disclosure regarding our controls and procedures as of September 30, 2012 in our Annual Report on Form 20-F for the year ended September 30, 2012.

**SUBMITTED HEREWITH**

<b>Exhibits</b>	
<u>99.1</u>	<u>Second Quarter Report Fiscal 2013</u>
<u>99.2</u>	<u>Certification of Interim Filings - CEO</u>
<u>99.3</u>	<u>Certification of Interim Filings - CFO</u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 15, 2013

**MERUS LABS INTERNATIONAL INC.**

*/s/ Andrew Patient*

---

Andrew Patient  
Chief Financial Officer